Literature DB >> 14600780

Pre-surgical mapping of primary motor cortex by functional MRI at 3 T: effects of intravenous administration of Gd-DTPA.

Shinji Naganawa1, Takashi Nihashi, Hiroshi Fukatsu, Takeo Ishigaki, Ikuo Aoki.   

Abstract

The functional magnetic resonance imaging (fMRI) is often performed at the end of a routine MRI examination during which, dependent on the clinical indication, contrast agent has been administered; however, the effects of Gd-DTPA injection on the results of blood oxygenation level dependent (BOLD)-fMRI remain unknown. The present study was conducted to investigate the effects of the intravenous administration of Gd-DTPA on the results of pre-surgical localization of the primary motor cortex by BOLD-fMRI at 3 T. Eight normal subjects were included in this study. After the anatomical scans, pre- and post-contrast fMRI scanning was performed. The number of significantly activated voxels and the mean percentage signal change were compared. The mean number of significantly activated voxels was 115.0+/-27.0 in pre-contrast runs and 90.8+/-27.1 in post-contrast runs (mean value of all 8 volunteers+/-standard deviation; p<0.05). The mean mean percentage signal change was 4.07+/-0.39 in pre-contrast runs and 3.86+/-1.91 in post-contrast runs ( p=0.16). Pre-surgical localization of the motor area by BOLD-fMRI should be performed before the administration of Gd contrast material.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14600780     DOI: 10.1007/s00330-003-2147-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  22 in total

1.  A qualitative test of the balloon model for BOLD-based MR signal changes at 3T.

Authors:  T Mildner; D G Norris; C Schwarzbauer; C J Wiggins
Journal:  Magn Reson Med       Date:  2001-11       Impact factor: 4.668

2.  A model of the coupling between brain electrical activity, metabolism, and hemodynamics: application to the interpretation of functional neuroimaging.

Authors:  Agnès Aubert; Robert Costalat
Journal:  Neuroimage       Date:  2002-11       Impact factor: 6.556

3.  Tolerance of extracellular contrast agents for magnetic resonance imaging.

Authors:  H J Weinmann; W R Press; H Gries
Journal:  Invest Radiol       Date:  1990-09       Impact factor: 6.016

4.  Differentiating between T1 and T2* changes caused by gadopentetate dimeglumine in the kidney by using a double-echo dynamic MR imaging sequence.

Authors:  V Y Kuperman; G S Karczmar; M J Blomley; M Z Lewis; L M Lubich; M J Lipton
Journal:  J Magn Reson Imaging       Date:  1996 Sep-Oct       Impact factor: 4.813

5.  Action of gadolinium complexes on different enzyme systems.

Authors:  M Allard; J M Caillé; B Bonnemain; D Meyer; G Simonnet
Journal:  Acta Radiol Suppl       Date:  1986

6.  Dietary caffeine consumption modulates fMRI measures.

Authors:  Paul J Laurienti; Aaron S Field; Jonathan H Burdette; Joseph A Maldjian; Yi-Fen Yen; Dixon M Moody
Journal:  Neuroimage       Date:  2002-10       Impact factor: 6.556

7.  1H chemical shift imaging reveals loss of brain tumor choline signal after administration of Gd-contrast.

Authors:  P E Sijens; M J van den Bent; P J Nowak; P van Dijk; M Oudkerk
Journal:  Magn Reson Med       Date:  1997-02       Impact factor: 4.668

8.  Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers.

Authors:  T Staks; G Schuhmann-Giampieri; T Frenzel; H J Weinmann; L Lange; J Platzek
Journal:  Invest Radiol       Date:  1994-07       Impact factor: 6.016

Review 9.  Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.

Authors:  E S Harpur; D Worah; P A Hals; E Holtz; K Furuhama; H Nomura
Journal:  Invest Radiol       Date:  1993-03       Impact factor: 6.016

10.  Functional magnetic resonance imaging of regional cerebral blood oxygenation changes during breath holding.

Authors:  A Kastrup; T Q Li; A Takahashi; G H Glover; M E Moseley
Journal:  Stroke       Date:  1998-12       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.